- Overview
- Key stats
- Stock price
- Financial performance
- Growth
- Valuations
- Efficiency
- Dividends
- Financial health
- Stocks
- Healthcare
- NASDAQ: ANIK
Price (delayed)
$14.85
Market cap
$210.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.83
Enterprise value
$178.9M
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...
Highlights
The company's EPS rose by 42% QoQ and by 32% YoY
The net income rose by 42% since the previous quarter and by 32% year-on-year
The company's gross profit rose by 28% QoQ but it fell by 8% YoY
Anika Therapeutics's gross margin has increased by 27% from the previous quarter but it has decreased by 7% YoY
ANIK's equity is down by 27% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of ANIK
MarketValuationsEarnings
Shares outstanding
14.18M
Market cap
$210.51M
Enterprise value
$178.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.41
Price to sales (P/S)
1.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.49
Revenue
$119.91M
Gross profit
$76M
Operating income
-$5.1M
Net income
-$56.39M
EBIT
-$52.66M
EBITDA
-$42.39M
Free cash flow
-$2.93M
Per shareBalance sheetLiquidity
EPS
-$3.83
EPS diluted
-$3.83
Free cash flow per share
-$0.2
Book value per share
$10.51
Revenue per share
$8.15
TBVPS
$13.12
Total assets
$202.74M
Total liabilities
$48.75M
Debt
$24.01M
Equity
$153.99M
Working capital
$90.35M
Debt to equity
0.16
Current ratio
4.88
Quick ratio
3.4
Net debt/EBITDA
0.75
MarginsEfficiencyDividend
EBITDA margin
-35.3%
Gross margin
63.4%
Net margin
-47%
Operating margin
-4.3%
Return on assets
-23.5%
Return on equity
-30%
Return on invested capital
-31.6%
Return on capital employed
-29.3%
Return on sales
-43.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIK stock price
How has the Anika Therapeutics stock price performed over time
Intraday
2.7%
1 week
2.91%
1 month
-1.33%
1 year
-46.18%
YTD
-9.78%
QTD
-1.2%
Financial performance
How have Anika Therapeutics's revenue and profit performed over time
Revenue
$119.91M
Gross profit
$76M
Operating income
-$5.1M
Net income
-$56.39M
Gross margin
63.4%
Net margin
-47%
ANIK financials
Anika Therapeutics's net margin has increased by 43% QoQ and by 31% YoY
The net income rose by 42% since the previous quarter and by 32% year-on-year
Anika Therapeutics's operating income has increased by 38% from the previous quarter
Anika Therapeutics's operating margin has increased by 38% from the previous quarter
Price vs fundamentals
Earnings waterfall
Growth
What is Anika Therapeutics's growth rate over time
ANIK growth chart
Valuation
What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.41
P/S
1.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.49
Valuation vs average
Price to earnings (P/E)
The company's EPS rose by 42% QoQ and by 32% YoY
Price to book (P/B)
ANIK's equity is down by 27% year-on-year and by 14% since the previous quarter
ANIK's price to book (P/B) is 22% less than its last 4 quarters average of 1.8 and 17% less than its 5-year quarterly average of 1.7
Price to sales (P/S)
ANIK's P/S is 46% below its 5-year quarterly average of 3.4 and 35% below its last 4 quarters average of 2.8
Efficiency
How efficient is Anika Therapeutics business performance
The company's return on sales rose by 41% QoQ and by 32% YoY
Anika Therapeutics's ROE has increased by 38% from the previous quarter and by 6% YoY
The return on assets has increased by 38% since the previous quarter and by 10% year-on-year
The ROIC is up by 36% since the previous quarter and by 26% year-on-year
Dividends
What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIK.
Financial health
How did Anika Therapeutics financials performed over time
Assets vs liabilities
The total assets has decreased by 25% YoY and by 12% QoQ
Anika Therapeutics's total liabilities has decreased by 16% YoY and by 5% from the previous quarter
Debt vs equity
Anika Therapeutics's debt is 84% lower than its equity
The debt to equity is up by 33% year-on-year and by 14% since the previous quarter
ANIK's equity is down by 27% year-on-year and by 14% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.